Cargando…

346. Evaluation of the Safety Profile of Cefazolin Monotherapy in Outpatient Parenteral Antibiotic Antimicrobial Therapy at a Large Academic Medical Center

BACKGROUND: The Infectious Diseases Society of America recommends serial safety lab monitoring during outpatient parenteral antimicrobial therapy (OPAT) to assess treatment response and prevent adverse events. However, these recommendations do not address the safety profile of specific antimicrobial...

Descripción completa

Detalles Bibliográficos
Autores principales: Poux, Nicolas, Gillett, Eric M, Franklin, Catherine, Estano, Mark J, Dewan, Charles, Sheedy, Kate, Dionne, Brandon, Kubiak, David W, Pearson, Jeffrey C, Chan, Brian T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677748/
http://dx.doi.org/10.1093/ofid/ofad500.417
_version_ 1785150203252178944
author Poux, Nicolas
Gillett, Eric M
Franklin, Catherine
Estano, Mark J
Dewan, Charles
Sheedy, Kate
Dionne, Brandon
Kubiak, David W
Pearson, Jeffrey C
Chan, Brian T
author_facet Poux, Nicolas
Gillett, Eric M
Franklin, Catherine
Estano, Mark J
Dewan, Charles
Sheedy, Kate
Dionne, Brandon
Kubiak, David W
Pearson, Jeffrey C
Chan, Brian T
author_sort Poux, Nicolas
collection PubMed
description BACKGROUND: The Infectious Diseases Society of America recommends serial safety lab monitoring during outpatient parenteral antimicrobial therapy (OPAT) to assess treatment response and prevent adverse events. However, these recommendations do not address the safety profile of specific antimicrobial agents or the ideal frequency of monitoring. Previous studies, using cohorts of fewer than 300 patients, report adverse event rates of less than 5% with outpatient cefazolin. It is possible that serial lab monitoring for patients on cefazolin monotherapy may represent unnecessary work and increase costs with minimal patient benefit. METHODS: A retrospective chart review was performed on patients treated with cefazolin monotherapy in the OPAT program of Brigham and Women’s Hospital (Boston, MA, USA) from February 2018 to February 2023. Data from weekly safety labs were examined during OPAT for the following abnormalities: change in creatinine (absolute increase of 0.5 mg/dL or relative increase ≥50%), ALT > 100 units/L, neutropenia (absolute neutrophil count < 1000 cells/mm(3)), eosinophilia ( >500 cells/mm(3)), and thrombocytopenia (< 100K/uL or relative decrease ≥50%). Other treatment complications adjudicated from chart review included antibiotic treatment changes, readmission, or mortality during OPAT. RESULTS: Among the 420 patients receiving cefazolin in OPAT, the median age was 62 (IQR: 49-71) years; 168 patients (40%) were women, and 62 (15%) were referred from oncology or transplant services. Twenty-four (6%) patients had at least one lab abnormality. Of these, 13 (3%) required a treatment change or had readmission or death. Eight (2%) cases were related to a lab abnormality, while five were due to other factors either unrelated to antibiotic therapy or apparent on clinical examination (e.g., rash). CONCLUSION: In an OPAT program at a large academic medical center, weekly lab monitoring altered clinical decision-making for 2% of patients on cefazolin monotherapy. It may be reasonable to reduce the frequency of or eliminate routine lab monitoring for these patients to reduce the cost of healthcare services. Future studies are indicated to evaluate the clinical impact of less frequent lab monitoring for OPAT patients on cefazolin monotherapy. DISCLOSURES: David W. Kubiak, PharmD, BCPS, BCIDP, FIDSA, Astellas Pharma, Inc.: Advisor/Consultant|AVIR Pharma Inc: Advisor/Consultant|Cidara Therapeutics: Advisor/Consultant|Shionogi Inc: Grant/Research Support
format Online
Article
Text
id pubmed-10677748
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106777482023-11-27 346. Evaluation of the Safety Profile of Cefazolin Monotherapy in Outpatient Parenteral Antibiotic Antimicrobial Therapy at a Large Academic Medical Center Poux, Nicolas Gillett, Eric M Franklin, Catherine Estano, Mark J Dewan, Charles Sheedy, Kate Dionne, Brandon Kubiak, David W Pearson, Jeffrey C Chan, Brian T Open Forum Infect Dis Abstract BACKGROUND: The Infectious Diseases Society of America recommends serial safety lab monitoring during outpatient parenteral antimicrobial therapy (OPAT) to assess treatment response and prevent adverse events. However, these recommendations do not address the safety profile of specific antimicrobial agents or the ideal frequency of monitoring. Previous studies, using cohorts of fewer than 300 patients, report adverse event rates of less than 5% with outpatient cefazolin. It is possible that serial lab monitoring for patients on cefazolin monotherapy may represent unnecessary work and increase costs with minimal patient benefit. METHODS: A retrospective chart review was performed on patients treated with cefazolin monotherapy in the OPAT program of Brigham and Women’s Hospital (Boston, MA, USA) from February 2018 to February 2023. Data from weekly safety labs were examined during OPAT for the following abnormalities: change in creatinine (absolute increase of 0.5 mg/dL or relative increase ≥50%), ALT > 100 units/L, neutropenia (absolute neutrophil count < 1000 cells/mm(3)), eosinophilia ( >500 cells/mm(3)), and thrombocytopenia (< 100K/uL or relative decrease ≥50%). Other treatment complications adjudicated from chart review included antibiotic treatment changes, readmission, or mortality during OPAT. RESULTS: Among the 420 patients receiving cefazolin in OPAT, the median age was 62 (IQR: 49-71) years; 168 patients (40%) were women, and 62 (15%) were referred from oncology or transplant services. Twenty-four (6%) patients had at least one lab abnormality. Of these, 13 (3%) required a treatment change or had readmission or death. Eight (2%) cases were related to a lab abnormality, while five were due to other factors either unrelated to antibiotic therapy or apparent on clinical examination (e.g., rash). CONCLUSION: In an OPAT program at a large academic medical center, weekly lab monitoring altered clinical decision-making for 2% of patients on cefazolin monotherapy. It may be reasonable to reduce the frequency of or eliminate routine lab monitoring for these patients to reduce the cost of healthcare services. Future studies are indicated to evaluate the clinical impact of less frequent lab monitoring for OPAT patients on cefazolin monotherapy. DISCLOSURES: David W. Kubiak, PharmD, BCPS, BCIDP, FIDSA, Astellas Pharma, Inc.: Advisor/Consultant|AVIR Pharma Inc: Advisor/Consultant|Cidara Therapeutics: Advisor/Consultant|Shionogi Inc: Grant/Research Support Oxford University Press 2023-11-27 /pmc/articles/PMC10677748/ http://dx.doi.org/10.1093/ofid/ofad500.417 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Poux, Nicolas
Gillett, Eric M
Franklin, Catherine
Estano, Mark J
Dewan, Charles
Sheedy, Kate
Dionne, Brandon
Kubiak, David W
Pearson, Jeffrey C
Chan, Brian T
346. Evaluation of the Safety Profile of Cefazolin Monotherapy in Outpatient Parenteral Antibiotic Antimicrobial Therapy at a Large Academic Medical Center
title 346. Evaluation of the Safety Profile of Cefazolin Monotherapy in Outpatient Parenteral Antibiotic Antimicrobial Therapy at a Large Academic Medical Center
title_full 346. Evaluation of the Safety Profile of Cefazolin Monotherapy in Outpatient Parenteral Antibiotic Antimicrobial Therapy at a Large Academic Medical Center
title_fullStr 346. Evaluation of the Safety Profile of Cefazolin Monotherapy in Outpatient Parenteral Antibiotic Antimicrobial Therapy at a Large Academic Medical Center
title_full_unstemmed 346. Evaluation of the Safety Profile of Cefazolin Monotherapy in Outpatient Parenteral Antibiotic Antimicrobial Therapy at a Large Academic Medical Center
title_short 346. Evaluation of the Safety Profile of Cefazolin Monotherapy in Outpatient Parenteral Antibiotic Antimicrobial Therapy at a Large Academic Medical Center
title_sort 346. evaluation of the safety profile of cefazolin monotherapy in outpatient parenteral antibiotic antimicrobial therapy at a large academic medical center
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677748/
http://dx.doi.org/10.1093/ofid/ofad500.417
work_keys_str_mv AT pouxnicolas 346evaluationofthesafetyprofileofcefazolinmonotherapyinoutpatientparenteralantibioticantimicrobialtherapyatalargeacademicmedicalcenter
AT gillettericm 346evaluationofthesafetyprofileofcefazolinmonotherapyinoutpatientparenteralantibioticantimicrobialtherapyatalargeacademicmedicalcenter
AT franklincatherine 346evaluationofthesafetyprofileofcefazolinmonotherapyinoutpatientparenteralantibioticantimicrobialtherapyatalargeacademicmedicalcenter
AT estanomarkj 346evaluationofthesafetyprofileofcefazolinmonotherapyinoutpatientparenteralantibioticantimicrobialtherapyatalargeacademicmedicalcenter
AT dewancharles 346evaluationofthesafetyprofileofcefazolinmonotherapyinoutpatientparenteralantibioticantimicrobialtherapyatalargeacademicmedicalcenter
AT sheedykate 346evaluationofthesafetyprofileofcefazolinmonotherapyinoutpatientparenteralantibioticantimicrobialtherapyatalargeacademicmedicalcenter
AT dionnebrandon 346evaluationofthesafetyprofileofcefazolinmonotherapyinoutpatientparenteralantibioticantimicrobialtherapyatalargeacademicmedicalcenter
AT kubiakdavidw 346evaluationofthesafetyprofileofcefazolinmonotherapyinoutpatientparenteralantibioticantimicrobialtherapyatalargeacademicmedicalcenter
AT pearsonjeffreyc 346evaluationofthesafetyprofileofcefazolinmonotherapyinoutpatientparenteralantibioticantimicrobialtherapyatalargeacademicmedicalcenter
AT chanbriant 346evaluationofthesafetyprofileofcefazolinmonotherapyinoutpatientparenteralantibioticantimicrobialtherapyatalargeacademicmedicalcenter